Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer

被引：0
|
作者：
Matthias Lang
Thomas Longerich
Chrysanthi Anamaterou
机构：
[1] University Hospital Heidelberg,Department of General
[2] University Hospital Heidelberg,, Visceral
[3] University of Heidelberg, and Transplant Surgery
来源：
Thyroid Research | / 16卷
关键词：
Anaplastic thyroid carcinoma; Vemurafenib; BRAF-inhibitor; Adjuvant targeted therapy; BRAF(V600E)-mutation; Review;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Multiple proliferation-survival signalling pathways are simultaneously active in BRAF V600E mutated thyroid carcinomas
    Rahman, Md Atiqur
    Salajegheh, Ali
    Smith, Robert Anthony
    Lam, Alfred King-yin
    EXPERIMENTAL AND MOLECULAR PATHOLOGY, 2015, 99 (03) : 492 - 497
  • [22] Response to Targeted Therapy in BRAF Mutant Anaplastic Thyroid Cancer
    Agarwal, Rishi
    Wang, Jiang
    Wilson, Keith
    Barrett, William
    Morris, John C.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2016, 14 (10): : 1203 - 1207
  • [23] Clinical, radiological and genomic features and targeted therapy in BRAF V600E mutant adult glioblastoma
    Lim-Fat, Mary Jane
    Song, Kun Wei
    Iorgulescu, J. Bryan
    Andersen, Brian M.
    Forst, Deborah A.
    Jordan, Justin T.
    Gerstner, Elizabeth R.
    Reardon, David A.
    Wen, Patrick Y.
    Arrillaga-Romany, Isabel
    JOURNAL OF NEURO-ONCOLOGY, 2021, 152 (03) : 515 - 522
  • [24] Clinical, radiological and genomic features and targeted therapy in BRAF V600E mutant adult glioblastoma
    Mary Jane Lim-Fat
    Kun Wei Song
    J. Bryan Iorgulescu
    Brian M. Andersen
    Deborah A. Forst
    Justin T. Jordan
    Elizabeth R. Gerstner
    David A. Reardon
    Patrick Y. Wen
    Isabel Arrillaga-Romany
    Journal of Neuro-Oncology, 2021, 152 : 515 - 522
  • [25] BRAF V600E-mutated lung adenocarcinoma with metastases to the brain responding to treatment with vemurafenib
    Robinson, Sara D.
    O'Shaughnessy, Joyce A.
    Cowey, C. Lance
    Konduri, Kartik
    LUNG CANCER, 2014, 85 (02) : 326 - 330
  • [26] Dabrafenib in patients with recurrent, BRAF V600E mutated malignant glioma and leptomeningeal disease
    Burger, Michael C.
    Ronelenfitsch, Michael W.
    Lorenz, Nadja I.
    Wagner, Marlies
    Voss, Martin
    Capper, David
    Tzaridis, Theophilos
    Herlinger, Ulrich
    Steinbach, Joachim P.
    Stoffels, Gabriele
    Langen, Karl-Josef
    Brandts, Christian
    Senft, Christian
    Harter, Patrick N.
    Baehr, Oliver
    ONCOLOGY REPORTS, 2017, 38 (06) : 3291 - 3296
  • [27] BRAF V600E mutations in papillary craniopharyngioma
    Brastianos, Priscilla K.
    Santagata, Sandro
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2016, 174 (04) : R139 - R144
  • [28] Vemurafenib for BRAF V600 mutated advanced melanoma: Results of treatment beyond progression
    Scholtens, A.
    Foppen, M. H. Geukes
    Blank, C. U.
    van Thienen, J. V.
    van Tinteren, H.
    Haanen, J. B.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 (05) : 642 - 652
  • [29] Antitumor effects of immunotherapy combined with BRAF and MEK inhibitors in BRAF V600E metastatic colorectal cancer
    Tak, Eunyoung
    An, Hye-In
    Lee, Amy Sinyoung
    Han, Kyuyoung
    Choi, Jiwan
    Kim, Hyung-don
    Hong, Yong Sang
    Kim, Sun Young
    Choi, Eun Kyung
    Kim, Jeong Eun
    Kim, Tae Won
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2025, 74 (05)
  • [30] Successful treatment of a BRAF V600E-mutant extracranial metastatic anaplastic oligoastrocytoma with vemurafenib and everolimus
    Shi, Liangliang
    Zou, Zhenwei
    Ding, Qian
    Liu, Qing
    Zhou, Hongxia
    Hong, Xiaohua
    Peng, Gang
    CANCER BIOLOGY & THERAPY, 2019, 20 (04) : 431 - 434
12345